Cancer Immunology, Immunotherapy

, Volume 60, Issue 5, pp 731–738 | Cite as

The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model

  • Brenda L. Soto
  • Jacquelyn A. Hank
  • Tyler J. Van De Voort
  • Lalita Subramanian
  • Arthur S. Polans
  • Alexander L. Rakhmilevich
  • Richard K. Yang
  • Songwong Seo
  • KyungMann Kim
  • Ralph A. Reisfeld
  • Stephen D. Gillies
  • Paul M. Sondel
Original Article

Abstract

We investigated the anti-tumor effect of peritumoral resveratrol in combination with immunotherapy in vivo in neuroblastoma-bearing mice. Subcutaneous NXS2 tumors were induced in A/J mice. On day 10, some mice received 15 mcg of intravenous immunocytokine for 5 days, mice received 20 mg of peritumoral resveratrol twice a week (starting on day 12) for a total of 5 injections, and a separate group received a combination of both regimens. Tumor progression and survival were assessed every 3–4 days. Blood and primary tumor tissue samples were collected on day 20 for Complete Blood Count and CD45 immunohistochemistry and histology, respectively. The primary tumor regressed in all mice receiving peritumoral resveratrol. Most of these mice receiving peritumoral resveratrol alone developed metastatic tumors and recurrence of the primary tumor after cessation of therapy. When resveratrol and immunocytokine regimens were combined, 61% of the mice receiving this combination therapy resolved their primary tumors and survived without developing metastatic tumors, compared to 15 and 13% receiving resveratrol or immunocytokine alone, respectively. None of the therapeutic regimes prevented lymphocyte infiltration or affected the complete blood count. Greater necrosis was observed microscopically in tumors from mice receiving the combination therapy. These results demonstrate that the combination therapy of peritumoral resveratrol plus intravenous immunocytokine provides better anti-tumor effects in this model than either therapy alone.

Keywords

Resveratrol Immunocytokine Anti-GD2 antibody Neuroblastoma Hu14.18-IL2 

References

  1. 1.
    van Ginkel PR, Sareen D, Subramanian L et al (2007) Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 13:5162–5169PubMedCrossRefGoogle Scholar
  2. 2.
    Chen Y, Tseng SH, Lai HS, Chen WJ (2004) Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136:57–66PubMedCrossRefGoogle Scholar
  3. 3.
    Busquets S, Ametller E, Fuster G et al (2007) Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 245:144–148PubMedCrossRefGoogle Scholar
  4. 4.
    Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 23:113–122CrossRefGoogle Scholar
  5. 5.
    Kimura Y, Okuda H (2001) Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 131:1844–1849PubMedGoogle Scholar
  6. 6.
    Liu HS, Pan CE, Yang W, Liu XM (2003) Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol 9:1474–1476PubMedGoogle Scholar
  7. 7.
    Neal ZC, Yang JC, Rakhmilevich AL et al (2004) Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10:4839–4847PubMedCrossRefGoogle Scholar
  8. 8.
    Yamane BH, Hank JA, Albertini MR, Sondel PM (2009) The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 18:991–1000PubMedCrossRefGoogle Scholar
  9. 9.
    Laverdière C, Liu Q, Yasui Y et al (2009) Long-term outcomes in survivors of neuroblastoma: a report from the childhood cancer survivor study. J Natl Cancer Inst 101:1131–1140PubMedCrossRefGoogle Scholar
  10. 10.
    Peters GJ, van der Vijgh WJ (1995) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur J Cancer 31A(Suppl 1):S1–S7PubMedCrossRefGoogle Scholar
  11. 11.
    Siebler T, Shalet SM, Robson H (2002) Effects of chemotherapy on bone metabolism and skeletal growth. Horm Res 58(Suppl 1):80–85PubMedCrossRefGoogle Scholar
  12. 12.
    Hank JA, Robinson RR, Surfus J et al (1990) Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant Interleukin-2. Cancer Res 50:5234–5239PubMedGoogle Scholar
  13. 13.
    Johnson EE, Lum HD, Rakhmilevich AL et al (2008) Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 57:1891–1902PubMedCrossRefGoogle Scholar
  14. 14.
    Neal ZC, Sondel PM, Bates MK, Gillies SD, Herweijer H (2007) Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory. Cancer Immunol Immunother 56:1765–1774PubMedCrossRefGoogle Scholar
  15. 15.
    Fuggetta MP, D’Atri S, Lanzilli G et al (2004) In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. Melanoma Res 14:189–196PubMedCrossRefGoogle Scholar
  16. 16.
    Kubota T, Uemura Y, Kobayashi M, Taguchi H (2003) Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res 23:4039–4046PubMedGoogle Scholar
  17. 17.
    Nicolini G, Rigolio R, Miloso M, Bertelli AA, Tredici G (2001) Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci Lett 302:41–44PubMedCrossRefGoogle Scholar
  18. 18.
    Wu SL, Sun ZJ, Yu L, Meng KW, Qin XL, Pan CE (2004) Effect of resveratrol in combination with 5-FU on murine liver cancer. Pharmacol Res 10:3048–3052Google Scholar
  19. 19.
    Boscolo P, del Signore A, Sabbioni E et al (2003) Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann Clin Lab Sci 33:226–231PubMedGoogle Scholar
  20. 20.
    Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G (2001) Effects of resveratrol on human immune cell function. Life Sci 70:81–96PubMedCrossRefGoogle Scholar
  21. 21.
    Feng YH, Zhou WL, Wu QL, Li XY, Zhao WM, Zou JP (2002) Low dose of resveratrol enhanced immune response of mice. Acta Pharmacol Sin 23:893–897PubMedGoogle Scholar
  22. 22.
    Gao X, Deeb D, Media J et al (2003) Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharamacol 66:2427–2435CrossRefGoogle Scholar
  23. 23.
    Prophet EB, Mills B, Arrington JB, Sobin, LH Laboratory Methods in Histotechnology. Armed Froces Intitutes of Pathology, Washington, pp 53–55Google Scholar
  24. 24.
    Dolfini E, Roncoroni L, Dogliotti E et al (2007) Resveratrol impairs the formation of MDA-MB-231 multicellular tumor spheroids concomitant with ceramide accumulation. Cancer Lett 249:143–147PubMedCrossRefGoogle Scholar
  25. 25.
    Signorelli P, Munoz-Olaya JM, Gagliostro V, Casas J, Ghidoni R, Fabriàs G (2009) Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett 282:238–243PubMedCrossRefGoogle Scholar
  26. 26.
    Ulrich S, Huwiler A, Loitsch S, Schmidt H, Stein JM (2007) De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. Biochem Pharmacol 74:281–289PubMedCrossRefGoogle Scholar
  27. 27.
    Minutolo F, Sala G, Bagnacani A et al (2005) Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells. J Med Chem 48:6783–6786PubMedCrossRefGoogle Scholar
  28. 28.
    Scarlatti F, Sala G, Ricci C et al (2007) Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 253:124–130PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Brenda L. Soto
    • 1
  • Jacquelyn A. Hank
    • 1
    • 5
  • Tyler J. Van De Voort
    • 1
  • Lalita Subramanian
    • 3
  • Arthur S. Polans
    • 3
  • Alexander L. Rakhmilevich
    • 1
    • 5
  • Richard K. Yang
    • 1
  • Songwong Seo
    • 5
  • KyungMann Kim
    • 4
    • 5
  • Ralph A. Reisfeld
    • 6
  • Stephen D. Gillies
    • 7
  • Paul M. Sondel
    • 1
    • 2
    • 5
    • 8
  1. 1.Department of Human OncologyUniversity of WisconsinMadisonUSA
  2. 2.Department of PediatricsUniversity of WisconsinMadisonUSA
  3. 3.Ophthalmology DepartmentUniversity of WisconsinMadisonUSA
  4. 4.Department of Biostatistics and Medical InformaticsUniversity of WisconsinMadisonUSA
  5. 5.Paul Carbone Comprehensive Cancer CenterUniversity of WisconsinMadisonUSA
  6. 6.Scripps Research InstituteLa JollaUSA
  7. 7.Provenance Biopharmaceuticals CorpWalthamUSA
  8. 8.Wisconsin Institute for Medical ResearchMadisonUSA

Personalised recommendations